CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden.
तुलना करने के लिए मीट्रिक्स | COMBI | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधCOMBIपीअर्सक्षेत्र | |
---|---|---|---|---|
पी/ई अनुपात | −1.4x | −2.5x | −0.7x | |
PEG अनुपात | −0.14 | −0.05 | 0.00 | |
क़ीमत/बुक | 0.6x | 1.4x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 16.7x | 10.9x | 3.2x | |
अपसाइड (विश्लेषक लक्ष्य) | - | 164.7% | 47.1% | |
उचित मूल्य अपसाइड | अनलॉक करें | 23.8% | 7.3% | अनलॉक करें |